1-2 of 2
Janet lyons-Lewis
Close
Sort by
Journal Articles

Bortezomib Consolidation Following Upfront ASCT for Multiple Myeloma Deepens Disease Response and MRD-Negative Rate without Compromising Response to Subsequent Bortezomib Salvage: Results of a Phase II Study

Oliver C Cohen, MBBS MRCP, Neil Rabin, Nicholas Counsell, Roger G Owen, MD PhD, Bilyana Popova, Oliver Schofield, Janet Lyons-Lewis, Andy Rawstron, Christopher Spence, Ruth Mary de Tute, PhD FRCPath, Derralynn Hughes, MRCP, MRCPath, DPhil, MA, Sally Moore, BSc, FRPATH, FRCP, MBBS, Paul Smith, PhD, Kwee L Yong
Journal: Blood
Blood (2016) 128 (22): 4508.
https://doi.org/10.1182/blood.V128.22.4508.4508
Published: 2016
Journal Articles

Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC)

Rakesh Popat, James D Cavenagh, MD, Roger G Owen, MD, Matthew Streetly, Stephen A Schey, MD, Mickey Koh, MD, Josephine Crowe, Michael F. Quinn, FRCPath, MB, MD MRCP, Shirley D'Sa, MD FRCP, FRCPath, Andres Virchis, Gordon Cook, MD PhD, Charles Crawley, Guy Pratt, Mark Cook, PhD FRCPath, Heather E. Oakervee, MBBS, BSc, MD MRCP, FRCPath, Nicholas Counsell, Toyin Adedayo, Alison Evans, Nivette Braganca, Paul Smith, MSc, Janet lyons-Lewis, Neil Rabin, Kwee L Yong, MBChB, PhD
Journal: Blood
Blood (2014) 124 (21): 4745.
https://doi.org/10.1182/blood.V124.21.4745.4745
Published: 2014